×

Contracts License Agreements

  • Apple cuts off Qualcomm

    Henry Blodget, Business Insider, and Scott Galloway, NYU Stern School of Business, discuss the dispute between Apple and Qualcomm over licensing.

  • *SBM's Monaco state backers keen on Japan- Galaxy president. TOKYO, March 29- Macau casino operator Galaxy Entertainment Group Ltd on Wednesday said it has partnered Societe des Bains de Mer, hoping the Monaco peer will help it trump rivals to win a license in Japan's nascent gambling market. "All of the entities of Monaco and the principality... are very enthusiastic...

  • NEW DELHI, March 28- Monsanto lost a legal battle with one of India's biggest seed producers over a contract dispute on Tuesday, and was ordered to restore a licensing agreement and cut royalty charges. The U.S. company's joint venture Mahyco Monsanto Biotech took Hyderabad- based Nuziveedu Seeds Ltd to court in 2015, claiming patent infringements and accusing...

  • WASHINGTON, March 22- A U.S. Senate committee easily passed a bill on Wednesday to enable the nuclear regulator to license advanced nuclear reactors that backers say are safer than conventional plants and can help deal with a growing waste problem. The bill has brought together some Republicans eager to prevent the United States from falling behind China and...

  • WASHINGTON, March 22- A U.S. Senate committee easily passed a bill on Wednesday to enable the nuclear regulator to license advanced nuclear reactors that backers say are safer than conventional plants and can help deal with a growing waste problem. The bill has brought together some Republicans eager to prevent the United States from falling behind China and...

  • Dec 19- Swiss drugmaker Novartis on Monday said it signed a licensing deal to co-develop a fatty liver disease drug with Conatus Pharmaceuticals Inc, under which the small U.S. company will receive $50 million up front. Conatus shares rose to $4.20 in extended trading from a Nasdaq close at $1.96. Conatus has the option to co-commercialize emricasan in the...

  • Dec 19- Swiss drugmaker Novartis on Monday said it signed a licensing deal to co-develop a fatty liver disease drug with Conatus Pharmaceuticals Inc, under which the small U.S. company will receive $50 million up front. Conatus has the option to co-commercialize emricasan in the United States. It is estimated that NASH affects 3 percent to 5 percent of the U.S....

  • Pandora CFO: A new paradigm for music consumption

    Michael Herring, CFO at Pandora, discusses the music streaming company's outlook as well as how Pandora stacks up against competitors.